| Assessment Status | Rapid Review complete |
| HTA ID | 24027 |
| Drug | Crovalimab |
| Brand | Piasky® |
| Indication | For the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): (i) In patients with haemolysis with clinical symptom(s) indicative of high disease activity; (ii) In patients who are clinically stable after having been treated with a complement 5 inhibitor for at least the past 6 months |
| Assessment Process | |
| Rapid review commissioned | 11/07/2024 |
| Rapid review completed | 01/08/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that crovalimab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations February 2026.